Fertility-sparing treatment for early cervical cancer
Prospective Study of Fertility-sparing Treatment Strategy in Patients With Early Cervical Cancer(SYSUGO-005/CSEM009)
This study is testing a treatment for early cervical cancer that helps women keep their ability to have children while effectively managing their cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | Female |
| Sponsor | Sun Yat-sen University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Guangzhou, Guangdong and 1 other locations) |
| Trial ID | NCT02624531 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients with early-stage cervical cancer (IB1-IIA2) who wish to preserve their fertility. It employs MRI scans to assess the absence of metastasis before treatment and determines the appropriate fertility-sparing surgical approach based on tumor size and response to neoadjuvant chemotherapy. The goal is to explore optimal treatment strategies that allow for effective cancer management while maintaining the potential for future pregnancies.
Who should consider this trial
Good fit: Ideal candidates are women diagnosed with early-stage cervical cancer (IB1-IIA2) who desire to preserve their fertility.
Not a fit: Patients with retroperitoneal lymph node metastasis, lower uterine involvement, or endometrial carcinoma will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enable women with early cervical cancer to retain their fertility while effectively treating their cancer.
How similar studies have performed: Other studies have explored fertility-sparing approaches in cervical cancer, showing promising results, but this specific strategy is still being evaluated.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with cervical cancer staging IB1-IIA2 desiring keeping their fertility function Exclusion Criteria: * retroperitoneal lymph node metastasis, involvement of lower part of uterus and endometrial carcinoma
Where this trial is running
Guangzhou, Guangdong and 1 other locations
- Clinical Trial Center — Guangzhou, Guangdong, China (Recruiting)
- Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Jihong Liu, PhD — Sun Yat-sen University
- Study coordinator: Yanling Feng, Doctor
- Email: fengyl@sysucc.org.cn
- Phone: +862013925090579
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.